Results 1 to 10 of about 59,116 (263)
Акушерство, гинекология и репродукция, 2016 Several direct oral anticoagulants (DOACs), namely, apixaban, rivaroxaban, and dabigatran etexilate, are currently licensed in Europe and the United States for various thromboembolic indications.
I. Tzoran, B. Brenner
doaj +3 more sources
Direct oral anticoagulants uptake and an oral anticoagulation paradox [PDF]
British Journal of Clinical Pharmacology, 2020 Oral anticoagulation (OAC) for stroke prevention in patients with atrial fibrillation is underutilised. One of the impediments to warfarin therapy is the frequent monitoring required, usually at a specialised warfarin clinic. The advent of direct oral anticoagulants (DOACs) facilitates OAC therapy without an onerous monitoring regimen. This benefit may
Cormac Kennedy +4 more
openaire +2 more sources
Safety and interaction of direct oral anticoagulants with antiarrhythmic drugs
Российский кардиологический журнал, 2021 The use of direct oral anticoagulants minimized the risks associated with vitamin K antagonist (warfarin) therapy. Currently, direct oral anticoagulants have priority over warfarin for the prevention of thromboembolic events in patients with atrial ...
B. A. Tatarsky, N. V. Kazyonnova
doaj +1 more source
IMPACT OF NON-VITAMIN K ORAL ANTI-COAGULANTS ON WARFARIN UTILISATION AND NHS BUDGET IN UK
Global Journal of Public Health Medicine, 2022 Introduction: Vitamin K anticoagulants were the mainstay prophylaxis of stroke in patients with atrial fibrillation and thromboembolic diseases. Non-vitamin K oral anticoagulants were approved for use in UK.
Mohammed Aladul +2 more
doaj +1 more source
Deutsches Ärzteblatt international, 2018 Much new evidence on oral anticoagulation has come to light in recent years. Non-vitamin-K-dependent oral anti- coagulants (NOAC) have been developed and have been introduced into clinical practice. In this review, we present the current state of the evidence on anticoagulation for various indications with vitamin K antagonists (VKA) and with NOAC.This
Ertunc, Altiok, Nikolaus, Marx
openaire +2 more sources
JRSM Open, 2021 Objective Several trials had compared the efficacy and safety between non-vitamin K antagonist oral anticoagulants and warfarin for acute venous thromboembolism, but the results were incomplete.
Yan Zhuang, Lin-feng Dai, Ming-qi Chen
doaj +1 more source
Xiehe Yixue Zazhi, 2022 Oral anticoagulants can effectively reduce the risk of stroke in patients with atrial fibrillation. However, patients with atrial fibrillation and chronic renal insufficiency have an increased risk in both stroke and bleeding, making anticoagulant ...
LI Xin +5 more
doaj +1 more source
Anatolian Journal of Cardiology, 2022 Background: The meta-analysis of randomized controlled trials has illustrated that the efficacy of low-dose non-vitamin K antagonist oral anticoagulants is inferior compared with standard-dose non-vitamin K antagonist oral anticoagulants, though they are
Zei Li +6 more
doaj +1 more source
Reviews in Cardiovascular Medicine, 2022 After reading with great interest the article entitled: “Non-vitamin K antagonist oral anticoagulants (NOACs) do not increase the risk of hepatic impairment in patients with non-valvular atrial fibrillation: insights from multi-source medical data ...
Aleksandr Urakov +4 more
doaj +1 more source
Novel oral anticoagulants [PDF]
International Journal of Clinical Practice, 2009 Oral anticoagulants have been used widely for the treatment of venous thromboembolism and stroke prevention. The vitamin K antagonists (VKAs), such as warfarin, have been around for the last 65 years and its efficacy as thromboprophylaxis remained largely unchallenged, at least until recently.
C W, Khoo +3 more
openaire +2 more sources